Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
Ronald G Collman · UNIVERSITY OF PENNSYLVANIA · 2019 · $3,512,603 — CFAR Overview ABSTRACT This competing renewal application for the Penn Center for AIDS Research (CFAR) builds on an outstanding record of dynamic scientific leadership, organizational structure, resources and infrastructure that advance HIV/AIDS research across the integrated campus of the Universit…
Gabriel D Victora · ROCKEFELLER UNIVERSITY · 2019 · $454,516 — PROJECT SUMMARY/ABSTRACT Germinal centers (GCs) are site of antibody somatic hypermutation (SHM) and affinity maturation, and are therefore essential for effective humoral immune responses to pathogens. Efficient affinity maturation in GCs requires that B cells cycle between two different cell state…
Sina A Gharib · UNIVERSITY OF WASHINGTON · 2019 · $871,221 — PROJECT SUMMARY Melioidosis, a tropical infection commonly manifesting as acute pneumonia and sepsis in humans, is caused by the Gram-negative Tier 1 select agent Burkholderia pseudomallei and represents a global public health threat with an estimated 165,000 cases and 89,000 deaths annually worldwi…
Paul Michael Armistead · UNIV OF NORTH CAROLINA CHAPEL HILL · 2019 · $456,823 — DESCRIPTION (provided by applicant): Chronic and acute leukemias are responsible for ~25,000 deaths annually in the US - a mortality rate that represents ~5% of all cancer related deaths. While leukemias are susceptible to antigen-specific T-cell mediated cytotoxicity, leukemia antigen (LA) di…
Richard B Kennedy · MAYO CLINIC ROCHESTER · 2019 · $777,489 — PROJECT SUMMARY/ABSTRACT This application is a request for funding of a research program focused on understanding the factors associated with waning immune response to mumps vaccine. Waning immunity to mumps is a public health concern and a major obstacle in the control and elimination of mumps dise…
Beatriz MA Fontoura · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2019 · $500,998 — DESCRIPTION (provided by applicant): Influenza viruses cause approximately 36,000 deaths annually in the United States and ~500,000 deaths worldwide per year. Strains that are extremely pathogenic have been responsible for high numbers of deaths worldwide, such as the 1918 pandemic which led to…
Joseph Patti · AGILVAX, INC. · 2019 · $845,852 — Agilvax’s AX09 is an Immunotherapy for Triple-Negative Breast Cancer: Agilvax is developing cancer immunotherapies and vaccines with its proprietary virus-like-particle (VLP) platform technology. Agilvax’s lead product, AX09, is an immunotherapy for triple-negative breast cancer (TNBC) targeting can…
Susan Leilani Fink · UNIVERSITY OF WASHINGTON · 2019 · $69,244 — Project Summary Zika virus (ZIKV) is a recently recognized global health threat due to the wide geographic distribution of risk and potential for severe consequences of infection. There remains no antiviral in clinical use for ZIKV, or any flavivirus, and many unanswered questions regarding the basi…
Nan-ping Peter Weng · NATIONAL INSTITUTE ON AGING · 2019 · $446,172 — A number of hallmarks of immune aging have been identified but underpinning causes are not fully understood. We analyzed three parameters (telomere length, inflammatory cytokines, and antibody titer to CMV) of immune system aging through a longitudinal analysis of 465 subjects ranging in age from 21…
Bernard Moss · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2019 · $772,992 — Poxviruses encode enzymes and factors needed for transcription and replication of their genomes within the cytoplasm of infected cells. Vaccinia virus, the prototypic member of the poxvirus family, provides a unique system for combining biochemical and genetic approaches for investigating mechanisms…
RICHARD CHILDS · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · 2019 · $3,775,841 — Approximately 19 years ago, we initiated the first ever clinical trail investigating allogeneic stem cell transplantation in patients with treatment refractory metastatic renal cell carcinoma (RCC). Definitive evidence for an allogeneic graft-versus-RCC effect has been demonstrated with complete reg…
George N. Pavlakis · DIVISION OF BASIC SCIENCES - NCI · 2019 · $1,436,310 — An important goal of this project continues to be the generation and testing of maximally efficient expression vectors for specific antigens. Our hypothesis is that the DNA vaccine dose is suboptimal for many human applications; therefore, increased efficiency is necessary for practical human DNA va…
THOMAS F GAJEWSKI · UNIVERSITY OF CHICAGO · 2019 · $221,729 — ABSTRACT The main purpose of the Human Immunologic Monitoring and Current Good Manufacturing Practice (HIM- cGMP) Facility is to provide support to investigators at the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) who conduct immunotherapy clinical trials through preparing vacc…
Leaf Huang · UNIV OF NORTH CAROLINA CHAPEL HILL · 2019 · $445,923 — Project 1 Abstract Cutaneous melanoma accounts for the majority (~75%) of skin cancer deaths. Despite the recent improvements in prevention and early detection, approximately 20% of patients with melanoma still die from the diseases. Patients with metastases have a poor prognosis and a very shor…
BRUCE L. LEVINE · UNIVERSITY OF PENNSYLVANIA · 2019 · $812,276 — SUMMARY CORE B: GMP CELL and RNA MANUFACTURING Core B is the Clinical Cell and Vaccine Production Facility (CVPF). The CVPF is a Foundation for the Accreditation of Cellular Therapy (FACT)-accredited, Good Manufacturing Practices (GMP) compliant cell and RNA manufacturing facility. This facility sup…
Kathryn M. Anastos · ALBERT EINSTEIN COLLEGE OF MEDICINE · 2019 · $70,819 — Investigations of HPV related malignancies are heavily dependent on laboratory testing, both to measure the outcomes (cancer, pre-cancer, intraepithelial neoplasia) and to define the possible predictors (e.g. high-risk HPV types). Several new molecular diagnostic tests are becoming available, includ…
Barton F. Haynes · DUKE UNIVERSITY · 2019 · $274,720 — The Administrative Core will coordinate the scientific and administrative activities of this IPCAVD Program, ensuring that the Projects and Cores function well together. In particular, it will be responsible for managing the program's financial management, program management, and coordinating Projec…
Barton F. Haynes · DUKE UNIVERSITY · 2019 · $727,666 — The overall goal of the Animal Models Core is to support all programs of the IPCAVD by performing immunization studies in CH58 unmutated common ancestor (UCA) VH + VL knock-in (KI) mice and rhesus macaques, with ALVAC-C vCP2438 prime and modified mRNA encoding trivalent mosaic gp120s for induction o…
Thomas Denny · DUKE UNIVERSITY · 2019 · $1,625,932 — HIV vaccine candidates entering into clinical testing generally fall into three categories: 1) recombinant envelope (Env) protein immunogens, 2) viral vectors, and 3) plasmid DNA. Numerous vaccine Env designs are being tested in clinical trials. Likewise, numerous HIV vaccine inserts, such as mosaic…
YANG XU · LUNA INNOVATIONS, INC. · 2019 · $1,999,997 — RNA-based vaccines and therapeutics have emerged as great promise for HIV prevention and treatment, respectively. However, many obstacles still need to be overcome, in particular RNA instability, manufacturing problems, and clinically relevant delivery mechanisms of RNA into target cells. RNA vaccin…